Labocanna Spolka Akcyjna Logo

Labocanna Spolka Akcyjna

Cultivates and distributes medical marijuana and cannabinoid products for clinical and consumer use.

LCN | WAR

Overview

Corporate Details

ISIN(s):
PLCCTLS00017 (+1 more)
LEI:
259400GAPNZTGIR9PK55
Country:
Poland
Address:
KOSZALIN MIESZKA I 49, 75-129 KOSZALIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Labocanna S.A. is a company operating in the hemp industry, focused on the cultivation, production, and distribution of cannabis-derived products. Its primary strategic goal is to produce medical marijuana for patients and clinical use, leveraging indoor cultivation methods. The company is also involved in creating new compounds and mixtures based on cannabinoids such as CBD, CBG, and CBC for various applications, including consumer goods. Labocanna aims to build an integrated 'ecological hub' of firms within the hemp market, with plans to manage extensive cultivation areas through acquisitions and partnerships. Some sources also indicate the company has operations in commercial real estate management.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-02-09 17:33
Regulatory News Service
Zawarcie przedwstępnej umowy na import marihuany medycznej - Content (PL)
Polish 2.3 KB
2024-02-09 08:40
M&A Activity
Rozwiązanie Umowy Inwestycyjnej w sprawie połączenia ze spółką Foxbuy.com S.A. …
Polish 806 bytes
2024-01-24 17:56
Declaration of Voting Results & Voting Rights Announcements
Lista akcjonariuszy, którzy wzięli udział w Walnym Zgromadzeniu oraz mieli co n…
Polish 810 bytes
2024-01-18 08:46
Regulatory News Service
Otrzymanie pisma z Instytutu Weterynaryjnego - Państwowego Instytutu Badawczego…
Polish 874 bytes
2024-01-02 17:24
Regulatory News Service
Wygaśnięcie umowy o zachowaniu poufności - Content (PL)
Polish 654 bytes
2023-12-28 17:28
Proxy Solicitation & Information Statement
Formularz dla pełnomocnika
Polish 133.8 KB
2023-12-28 17:28
Pre-Annual General Meeting Information
Proponowane zmiany statutu Labocanna S.A.
Polish 183.6 KB
2023-12-28 17:28
Pre-Annual General Meeting Information
Projekty uchwał na NWZA Labocanna S.A.
Polish 221.4 KB
2023-12-28 17:28
Pre-Annual General Meeting Information
Ogłoszenie o NWZA Labocanna S.A.
Polish 99.3 KB
2023-12-28 17:28
Pre-Annual General Meeting Information
ogłoszenie o zwołaniu NWZ na dzień 24 stycznia 2024 r. wraz z projektami uchwał…
Polish 469 bytes
2023-12-28 16:49
Major Shareholding Notification
Lista akcjonariuszy, którzy wzięli udział w Walnym Zgromadzeniu oraz mieli co n…
Polish 603 bytes
2023-12-20 18:02
Share Issue/Capital Change
Założenie spółki zależnej - Content (PL)
Polish 1.0 KB
2023-12-01 15:37
Proxy Solicitation & Information Statement
Formularz dla pełnomocnika na NWZA
Polish 132.6 KB
2023-12-01 15:37
Registration Form
Proponowane zmiany statutu na NWZA
Polish 204.9 KB
2023-12-01 15:37
Post-Annual General Meeting Information
Projekty uchwła na NWZA
Polish 246.8 KB

Automate Your Workflow. Get a real-time feed of all Labocanna Spolka Akcyjna filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Labocanna Spolka Akcyjna via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.